CURE Pharmaceutical Welcomes Researcher and Innova

OXNARD, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs), today announces the appointment of Michael Neely, MD, 47, to its Advisory Board. “By joining CURE's advisory board, I'm truly excited by the prospect of helping to shape the future of medication formulation,” said Dr. Neely. “As a pediatric infectious diseases physician, clinical pharmacologist, and scientist, I know it's time for a profound revolution to optimize how all patients take their medications.  I believe CURE can be instrumental in this change.”

Michael Neely, MD, currently serves as acting chief of infectious diseases and director of the Laboratory of Applied Pharmacokinetics and Bioinformatics (LAPKB) at the Children's Hospital of Los Angeles, and as associate professor of pediatrics and clinical scholar at the University of Southern California (USC) Keck School of Medicine.  He also works with multidisciplinary faculty collaborators in the USC Departments of Pediatrics, Medicine, and Preventive Medicine, as well as in the School of Pharmacy. His research and clinical interests include pediatric clinical pharmacometrics, population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, biomarker control, simulation, and most importantly, use of models to optimize therapy for individual patients. As a result of these interests, he created Pmetrics, a non-parametric and parametric population modeling and simulation package for R.  He also created an R package for BestDose, which is software to optimize drug therapy for individual patients.

Dr. Neely has a Master’s of Science in Clinical and Biomedical Investigations from University of Southern California, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling.  He was also a member of the United States Food and Drug Administration Anti-infective Drug Advisory Committee, and now periodically consults for the committee. He is a Regent of the American College of Clinical Pharmacology, a founding member of the International Society of Pharmacometrics, and an active member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.  

Finally, Dr. Neely has been the principal investigator on an NIH K23 training grant, two R01s, and is co-PI of a third R01, as well as co-investigator on other NIH grants, with continuous NIH funding since 2007.  He has published more than 100 peer-reviewed articles, mentored numerous visiting scholars, and is an invited speaker worldwide. 

“Michael’s depth of experience as a researcher in the field of pediatric infectious disease, clinical trial design, medical statistical analysis and FDA collaboration are all important assets that will help to propel CURE’s development forward,” said Rob Davidson, CEO of CURE Pharmaceutical. “We are grateful for his guidance, and look forward to utilizing his experience.”

About CURE Pharmaceutical Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility.  CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules.   The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index.  CURE Pharmaceutical is traded under the symbol CURR.  For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com .

Forward-looking statements This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.com